Trichosporon Asahii. Blood-stream infection in a non-cancer patient receiving combination antifungal therapy

Ulster Medical Journal

Volumn 75, Issue 3, 2006, Pages 226-227

  O'Gorman, Ciaran ^a   McMullan, R ^a   Webb, C H ^a   Bedi, A ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CIPROFLOXACIN; FLUCONAZOLE; GENTAMICIN; MEROPENEM; VORICONAZOLE;

ABOVE KNEE AMPUTATION; ACUTE KIDNEY FAILURE; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BLOOD CLOTTING DISORDER; BLOOD CULTURE; CASE REPORT; COMORBIDITY; CRUSH TRAUMA; ENTEROBACTER CLOACAE; FATALITY; HEMODIALYSIS; HUMAN; INOTROPISM; INTENSIVE CARE UNIT; LAPAROTOMY; MALE; METABOLIC ACIDOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; SEPSIS; TREATMENT OUTCOME; TRICHOSPORON ASAHII; VASCULAR SURGERY;

ACCIDENTS, OCCUPATIONAL; AGED; AGRICULTURE; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HUMANS; MALE; MULTIPLE ORGAN FAILURE; MYCOSES; PEPTIDES, CYCLIC; SEPSIS; SPECIES SPECIFICITY; TRICHOSPORON;

EID: 33748183239     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Ebright JR, Fairfax MR, Vazquez JA. Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia. Clin Infect Dis 2001;33(5):E28-30.
2. Krcmery V, Jr., Mateicka F, Kunova A, Spanik S, Gyarfas J, Sycova Z et al. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol. Support Care Cancer 1999;7(1):39-43.
3. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards: Wayne, PA, USA, 1996.
4. Sugita T, Nishikawa A, Ichikawa T, Ikeda R, Shinoda T. Isolation of Trichosporon asahii from environmental materials. Med Mycol 2000;38(1):27-30.
5. Chan-Tack KM. Fatal Trichosporon asahii septicemia in a Guatemalan farmer with acute lymphoblastic leukemia. South Med J 2005;98(9):954-5.
6. Wolf DG, Falk R, Hacham M, Theelen B, Boekhout T, Scorzetti G et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol 2001;39(12):4420-5.
7. Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2002;21(12):892-6.
8. Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004;36(8):564-9.
9. Ramos JM, Cuenca-Estrella M, Gutierrez F, Elia M, Rodriguez-Tudela JL. Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism. J Clin Microbiol 2004;42(5):2341-4.
10. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36(10):2950-6.
11. Falk R, Wolf DG, Shapiro M, Polacheck I. Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol 2003;41(2):911.